Print Send My Information

Purpose

The purpose of this registry is to evaluate real world experience and outcomes of patients with Upper Tract Urothelial Cancer (UTUC) treated with Jelmyto in the United States.

Conditions

Eligibility

Eligible Ages
Over 18 Years
Eligible Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Adults >18 years old and capable of giving informed consent. - Diagnosis of UTUC. - Receipt of at least 1 dose of JELMYTO after FDA approval (15 Apr 2020).

Exclusion Criteria

  • Incapable of giving informed consent (e.g., incarcerated individuals, individuals with dementia). - Receipt of 1 or more doses of JELMYTO (also referred to as UGN-101 or Mitogel in clinical development) before FDA approval (on or before 15 Apr 2020). - Pregnancy or lactation. - Unable to comply with protocol requirements (for prospective data capture). - Any medical or mental condition(s) that makes participation in the Registry inadvisable in the opinion of the Investigator (for prospective data capture).

Study Design

Phase
Study Type
Observational [Patient Registry]
Observational Model
Cohort
Time Perspective
Other

Arm Groups

ArmDescriptionAssigned Intervention
Jelmyto Patients with UTUC treated with Jelmyto
  • Drug: Jelmyto (mitomycin) for pyelocalyceal solution
    The dose of Jelmyto to be instilled is 4 mg per mL via ureteral catheter or a nephrostomy tube, with total instillation volume based on volumetric measurements using pyelography, not to exceed 15 mL (60 mg of mitomycin). Instill Jelmyto once weekly for six weeks. For patients with a complete response 3 months after Jelmyto initiation, Jelmyto instillations may be administered once a month for a maximum of 11 additional instillations.
    Other names:
    • Jelmyto
    • UGN-101

Recruiting Locations

Providence St. Johns Health Center
Santa Monica 5393212, California 5332921 90404
Contact:
Jennifer Linehan, MD
Jennifer.linehan@providence.org

University of Florida
Gainesville 4156404, Florida 4155751 32610
Contact:
Padraic OMalley, MD
352-265-8240
Padraic.O'Malley@urology.ufl.edu

Mount Sinai Medical Center of Florida, Inc.
Miami 4164138, Florida 4155751 33140
Contact:
Alan Nieder, MD
Alan.Nieder@msmc.com

H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc.
Tampa 4174757, Florida 4155751 33612
Contact:
Wade Sexton, MD
Wade.Sexton@moffitt.org

Northwestern University
Chicago 4887398, Illinois 4896861 60611
Contact:
Joshua Meeks, MD
joshua.meeks@northwestern.edu

Indiana University
Indianapolis 4259418, Indiana 4921868 46202
Contact:
Hristos Kaimakliotis, MD
hkaimakl@iupui.edu

The State University of Iowa
Iowa City 4862034, Iowa 4862182 52242
Contact:
Michael ODonnell, MD
michael-odonnell@uiowa.edu

Chesapeake Urology
Baltimore 4347778, Maryland 4361885 21204
Contact:
Rian Dickstein, MD
rdickstein@chesuro.com

Johns Hopkins Medical Center
Baltimore 4347778, Maryland 4361885 21287
Contact:
Nirmish Singla, MD
410-955-6100

Mass General Hospital (MGH)
Boston 4930956, Massachusetts 6254926 02114
Contact:
Adam Feldman, MD
afeldman@mgb.org

The Brigham and Womens Hospital
Boston 4930956, Massachusetts 6254926 02115
Contact:
Steven Chang, MD
SLCHANG@BWH.HARVARD.EDU

University of Michigan
Ann Arbor 4984247, Michigan 5001836 48109
Contact:
Khurshid Ghani, MD
kghani@med.umich.edu

University of Missouri
Columbia 4381982, Missouri 4398678 65211
Contact:
Eliza DeFroda, MD
elddmc@health.missouri.edu

Rutgers
New Brunswick 5101717, New Jersey 5101760 08903
Contact:
Saum Ghodoussipour, MD
sg1621@cinj.rutgers.edu

The Feinstein Institutes for Medical Research
Lake Success 5123853, New York 5128638 11042
Contact:
David Hoenig, MD
dhoenig@northwell.edu

NYU Grossman School of Medicine
New York 5128581, New York 5128638 10016
Contact:
Katie Murray, MD
Katie.Murray@nyulangone.org

SUNY Upstate
Syracuse 5140405, New York 5128638 13210
Contact:
Joseph Jacob, MD
JacobJ@upstate.edu

The University of North Carolina Chapel Hill
Chapel Hill 4460162, North Carolina 4482348 27599
Contact:
Marc Bjurlin, MD
marc_bjurlin@med.unc.edu

Ohio State University
Columbus 4509177, Ohio 5165418 43202
Contact:
Ahmad Shabsigh, MD
614-685-4263
Ahmad.Shabsigh@osumc.edu

Medical University of South Carolina
Charleston 4574324, South Carolina 4597040 29425
Contact:
Karthik Tanneru, MD
tanneru@musc.edu

UT Southwestern Medical Center
Dallas 4684888, Texas 4736286 75390
Contact:
Brett Johnson, MD
Brett.Johnson@UTSouthwestern.edu

The University of Texas M.D. Anderson Cancer Center
Houston 4699066, Texas 4736286 77030
Contact:
Mehrad Adibi, MD
MAdibi@mdanderson.org

More Details

NCT ID
NCT05874921
Status
Recruiting
Sponsor
UroGen Pharma Ltd.

Study Contact

Michael Louie, MD, MPH, MSc
855-987-6436
registry@urogen.com

Detailed Description

Patients may be enrolled prospectively, at the time of receiving Jelmyto, or after receiving Jelmyto for retrospective data capture and prospective follow up. Patients will be followed until 3 years after the first dose of Jelmyto or death. Data will be captured to address specific clinical questions and data gaps related to real world use of Jelmyto. Example clinical questions: 1. How is Jelmyto used in the real world setting? 2. What adverse events (AEs) and at what rates and time points are they observed in the real world setting? 3. What is the disease volume before and after resection/ablation prior to treating with Jelmyto? 4. Did the use of Jelmyto impact clinical decision making and management? 5. What is the complete response (CR) rate, duration of response, and rate of progression, including subgroups of interest? 6. What are the rates of, time to, and pathology at radical nephroureterectomy (RNU) by response to treatment and number of Jelmyto doses received? 7. What are outcomes for non-responders or partial responders? What are the rates of surgical and therapeutic treatment options received following response assessment, including additional Jelmyto? 8. What was the outcome of patients with solitary kidney and/or chronic kidney disease (CKD)? Did Jelmyto prevent dialysis by avoiding nephrectomy in solitary kidney or in patients with baseline CKD? 9. What is the rate and timing of bladder cancer occurrence and/or recurrences?

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.

For help using this page: trialstoday@researchmatch.org or call 855-514-7001

ResearchMatch is funded in part by the National Institutes of Health (NIH) Clinical and Translational Science Award (CTSA) program, led by the NIH’s National Center for Advancing Translational Sciences (NCATS), grants UL1TR000445 and 1U54RR032646-01, and grant U24TR001579 from NCATS and the National Library of Medicine. The content of this website is solely the responsibility of ResearchMatch and Vanderbilt University and does not necessarily represent the official views of the NIH, NCATS, or NLM.

Vanderbilt University Medical Center